Back

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2023

- 20 June 2023 - 1 mins read

 Aggregated presentation by day and by market

Name of issuer Identification code of issuer (Legal Entity Identifier) Day of transaction Identification code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares * Market (MIC Code)
IPSEN 549300M6SGDPB4Z94P11 12/06/2023 FR0010259150 260 111.72 AQEU
IPSEN 549300M6SGDPB4Z94P11 12/06/2023 FR0010259150 960 111.40 CEUX
IPSEN 549300M6SGDPB4Z94P11 12/06/2023 FR0010259150 588 111.57 TQEX
IPSEN 549300M6SGDPB4Z94P11 12/06/2023 FR0010259150 2,892 111.57 XPAR
IPSEN 549300M6SGDPB4Z94P11 13/06/2023 FR0010259150 808 111.08 AQEU
IPSEN 549300M6SGDPB4Z94P11 13/06/2023 FR0010259150 1,143 111.13 CEUX
IPSEN 549300M6SGDPB4Z94P11 13/06/2023 FR0010259150 669 111.22 TQEX
IPSEN 549300M6SGDPB4Z94P11 13/06/2023 FR0010259150 3,430 111.15 XPAR
IPSEN 549300M6SGDPB4Z94P11 14/06/2023 FR0010259150 659 111.15 AQEU
IPSEN 549300M6SGDPB4Z94P11 14/06/2023 FR0010259150 1,148 111.04 CEUX
IPSEN 549300M6SGDPB4Z94P11 14/06/2023 FR0010259150 398 111.14 TQEX
IPSEN 549300M6SGDPB4Z94P11 14/06/2023 FR0010259150 4,195 111.03 XPAR
IPSEN 549300M6SGDPB4Z94P11 15/06/2023 FR0010259150 1,034 110.72 AQEU
IPSEN 549300M6SGDPB4Z94P11 15/06/2023 FR0010259150 1,504 110.67 CEUX
IPSEN 549300M6SGDPB4Z94P11 15/06/2023 FR0010259150 584 110.65 TQEX
IPSEN 549300M6SGDPB4Z94P11 15/06/2023 FR0010259150 4,678 110.57 XPAR
IPSEN 549300M6SGDPB4Z94P11 16/06/2023 FR0010259150 210 111.17 AQEU
IPSEN 549300M6SGDPB4Z94P11 16/06/2023 FR0010259150 387 111.89 CEUX
IPSEN 549300M6SGDPB4Z94P11 16/06/2023 FR0010259150 223 112.19 TQEX
IPSEN 549300M6SGDPB4Z94P11 16/06/2023 FR0010259150 1,947 112.10 XPAR
             
* Two-digit rounding after the decimal   TOTAL 27,717 111.13  

Attachment

Related Press Releases

Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
16 June 2023 6 mins read

Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance
16 June 2023 4 mins read

Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance
Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
14 June 2023 9 mins read

Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
14 June 2023 9 mins read

Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
13 June 2023 8 mins read

U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2023
13 June 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
09 June 2023 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital